Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00384527 · ClinicalTrials.gov registry record · Phase 3
Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease
A Phase 3 study, sponsored by Romark Laboratories L.C..
- Terminated
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
NCT00384527 is a Phase 3 study that was terminated before completion, run by Romark Laboratories L.C.. The registered enrollment target is 50 participants.
The verdict
NCT00384527, a Phase 3 study, was terminated before completion, sponsored by Romark Laboratories L.C..
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
Study Summary
The primary objective of the study is to demonstrate non-inferiority of nitazoxanide compared to vancomycin in resolving symptoms of Clostridium difficile-associated disease (CDAD).
Interventions
- DRUG Vancomycin
- DRUG Nitazoxanide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2006-12 |
| Est. Completion | 2007-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00384527
The ClinicalTrials.gov registry entry for NCT00384527 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Romark Laboratories L.C., which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vancomycin is the first listed.
NCT00384527 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00384527 about?
NCT00384527 is a clinical study titled "Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease". The primary objective of the study is to demonstrate non-inferiority of nitazoxanide compared to vancomycin in resolving symptoms of Clostridium difficile-associated disease (CDAD).
What is the current status of trial NCT00384527?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2006-12. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00384527?
The interventions under investigation include: Vancomycin (DRUG), Nitazoxanide (DRUG).
Who is sponsoring clinical trial NCT00384527?
This trial is sponsored by Romark Laboratories L.C., which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.